The Obesity ETF (SLIM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea. The post Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders.
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. Tirzepatide's clinical trial updates were very positive this year, including the results from the head-to-head showing superiority trial to Novo Nordisk's semaglutide. With CagriSema underperforming expectations this week, the risk of a product superior to tirzepatide coming to market in the next few years is greatly reduced.
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped The post Novo Nordisk Dives On CagriSegma Obesity Drug Trial.
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
The experimental obesity drug CagriSema disappointed investors.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk's dominance in the weight-loss market.
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
On Friday, BioAge Labs Inc. BIOA announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Per Lilly, this is its single-largest manufacturing investment in the country outside its home state. It plans to start construction on the expansion next year.
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd draw based on the top holdings of the billionaire's Millennium Management hedge fund.
Viking Stock Pops, Then Drops On Latest Obesity / MASH Data - Why I'm Still Bullish
Viking Therapeutics is a strong contender in the GLP-1 obesity drug market - candidate VK2735 has the potential to challenge Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The latest data from the oral and subq versions of Viking's drug are encouraging, albeit pivotal studies must still be arranged and negotiated successfully. If approved, VK2735 will need to show it has a best-in-class profile in terms of either durability, dosing regimen, side-effect profile, price or mode of administration.
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.
